QIAGEN NV Hits 52-Week Low at USD 33.82 Amidst Declining Performance

QIAGEN NV, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 33.82 as of April 28, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 26.3%, contrasting sharply with the S&P 500's gain of 29.12% during the same period. Despite its challenges, QIAGEN maintains a market capitalization of USD 8,497 million and exhibits a price-to-earnings (P/E) ratio of 18.00. The company has demonstrated a strong ability to manage its debt, reflected in a low debt-to-equity ratio of 0.15 and a favorable debt-to-EBITDA ratio of 0.91 times. Additionally, QIAGEN's return on equity stands at 12.51%, indicating efficient use of shareholder funds. While the stock has faced consistent underperformance against market benchmarks over the last three years, it has shown resilience in its operating cash flow, which peaked at USD 675.04 million. The company's price-to-book ratio is 2.25, suggesting a valuation that may be attractive compared to its peers.